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ABSTRACT  
Background: Several aspects of volitional control of action may be relevant in the 
pathophysiology of impulsive-compulsive behaviours (ICB) in Parkinson’s disease (PD). 
We aimed to explore multiple aspects of action control, assessing reward-related 
behaviour, inhibition (externally and internally triggered) and sense of agency in PD 
patients, with and without ICB compared to healthy subjects.  
Methods: Nineteen PD patients with ICB (PD-ICB), 19 PD without ICB (PD-no-ICB) and 
19 healthy controls (HC) underwent a battery of tests including: Intentional Binding task 
which measures sense of agency; Stop Signal Reaction Time (SSRT) measuring capacity 
for reactive inhibition; the Marble task, assessing intentional inhibition; Balloon Analog Risk 
Task for reward sensitivity.  
Results: One-way ANOVA showed significant main effect of group for action binding (p= 
0.004, F=6.27). Post hoc analysis revealed that PD-ICB had significantly stronger action 
binding than HC (p=0.004), and PD-no-ICB (p=0.04).  There was no difference between 
PD-no-ICB and HC. SSRT did not differ between PD groups, whereas a significant 
difference between PD-no-ICB and HC was detected (p=0.01). No other differences were 
found among groups in the other tasks. 
Conclusions: PD patients with ICB have abnormal performance on a psychophysical task 
assessing sense of agency, which might be related to a deficit in action representation at 
cognitive/experiential level. Yet, they have no deficit on tasks evaluating externally and 
internally triggered inhibitory control, or in reward-based decision-making. We conclude 
that impaired sense of agency may be a factor contributing to ICB in PD patients. 
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INTRODUCTION 
Impulsive compulsive behaviours (ICBs) are common neuropsychiatric complications of 
PD associated with dopaminergic treatment, particularly with dopamine agonists [1]. ICBs 
include impulse control disorders (ICD) such as pathological gambling, hypersexuality, 
compulsive buying and binge eating, and compulsive behaviours such as punding and 
compulsive use of dopamine replacement therapy (also known as dopamine dysregulation 
syndrome, DDS). ICDs are defined as behaviours that are performed repetitively, 
excessively, and compulsively to an extent that they interfere with major areas day to day 
functioning and have been characterised as behavioural addictions [1]. Although ICDs 
have been linked to the use of dopamine agonists, clinical and experimental evidence 
suggest that they are unlikely to be a purely drug-induced phenomenon. Current 
hypotheses propose an interaction between chronic administration of dopaminergic drugs 
and disease specific effects on the brain network involved in reward [2]. Impaired reward-
reinforcement learning [3], increased impulsivity and poor self-control [4], have been 
demonstrated in PD with ICD. It has been hypothesized that in predisposed PD patients, 
dopaminergic treatment, particularly with dopamine agonists, might enhance risk-taking 
behavior [5,6], impair learning from negative feedback [7] and promote impulsive decision-
making [8].  
Although impairment of reward-related behavior plays a role in the development of ICD in 
PD, value-related computations are only one aspect of decision-making. Voluntary actions 
typically aim at bringing about some goal or outcome and successful actions are 
accompanied by a characteristic “sense of agency”.  This refers to the subjective 
experience that an action and its outcome, were under one’s own voluntary control. The 
ability to link an external outcome to an intentional action comprises both the feeling of 
having initiated the action and an attribution of the outcome to one’s own action, rather 
than any other cause [9]. Accordingly, altered sense of agency is a feature of many 
neuropsychiatric conditions [10]. The temporal binding task has been proposed by 
Haggard and co-workers [11] as an implicit marker of sense of agency. In the binding task, 
subjects make judgements about the perceived time of actions and of tones that follow the 
voluntary action. Intentional actions are perceived to occur later in time and their effects 
(i.e. tones) are perceived to occur earlier in time compared to their respective baseline 
conditions in which the action occurs without the subsequent tone, or the tone occurs 
without being triggered by any action. Importantly, this temporal attraction between self 
generated actions and their outcomes was absent when the voluntary action was replaced 
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by an involuntary movement. For this reason, the ‘intentional binding effect’ has been 
suggested to be a quantitative yet implicit index of awareness of action or agency [9,11]. 
The ability to inhibit an action is a further fundamental aspect of voluntary control.  Many 
classical experimental paradigms involve preparing an action, but then withholding it in 
response to an external signal (e.g. stop signal reaction time tasks). However, the capacity 
to decide internally to inhibit an action, in the absence of any external instruction, is 
arguably more important for self-control.  Internally driven action inhibition is difficult to 
assess experimentally.  One cognitive model of action control [12] hypothesises a ‘whether 
decision’, distinct from decisions about what action to make, and when to make it. The 
“whether decision” could trigger a process of intentional inhibition of actions that have 
been prepared, but should now be withheld. Experimental paradigms to probe this aspect 
of internal action inhibition have been proposed [13]. 
Our aim was to perform a comprehensive assessment of voluntary control of action with 
assessments of sense of agency, action inhibition (both internally and externally triggered) 
and reward-related decision-making in PD patients with and without ICB compared to a 
control group of healthy participants. 
METHODS 
Thirty-eight PD patients were included in the study. Inclusion criteria were: a diagnosis of 
PD according to UK Parkinson’s Disease Society Brain Bank criteria; treatment and clinical 
condition stable for at least 4 weeks prior to the study. Exclusion criteria were: any major 
concurrent neurological or psychiatric disorders; a score < 25 on the Montreal Cognitive 
Assessment (MOCA). The sample of patients included: 19 PD patients without ICB (PD-
no-ICB) and 19 PD patients with ICB (PD-ICB). A semi-structured interview using 
accepted diagnostic criteria[14] for pathological gambling, compulsive buying, compulsive 
sexual behaviour, binge eating, punding and DDS (anytime in the past 6 months) was 
employed to reach the diagnosis of each of these ICB. Accordingly, among PD-ICB 
patients, one had an isolated ICD (hypersexuality), all the remaining patients presenting at 
least 2 ICB (pathological gambling = 4, compulsive sexual behaviour = 12, compulsive 
shopping = 11, binge eating = 8, punding = 11, DDS = 3). All ICB patients reported ICD. 
Nineteen healthy control subjects (HC) (matched for age, gender and education level) 
were also recruited as a control group. Individuals with a history of any major concurrent 
neurological or psychiatric disorders were excluded. Patients and HC gave written, 
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informed consent. Institutional ethics approval was obtained and the experiment was 
conducted in accordance with the Declaration of Helsinki.  
The following variables were retrieved: educational level, age at study entry, age at 
disease onset, disease duration. Levodopa and dopamine-agonist use (D-Ag) equivalent 
daily dose (LEDD) was calculated [15]. Disease severity and stage were respectively rated 
by means of the Unified Parkinson’s Disease Rating Scale and the Hoehn and Yahr scale. 
The questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP-
RS)[16] was employed to evaluate severity of ICB. All patient were tested in their ‘‘best 
ON’’ state (the best motor state at peak effect after taking their usual medication dose). 
Beck Depression Inventory (BDI), Hamilton Anxiety Rating Scale (HAM-A), Apathy 
Evaluation Scale (AES) were employed to rate respectively depression, anxiety and 
apathy. Besides testing of overall cognitive function by means of the MOCA, all subjects 
underwent the following battery of tests for specific cognitive functions: (1) working 
memory: digit span forward and backward; 2) executive functions and attention: 
phonological word fluency; categorical word fluency; Trail Making Test A and B; 3) and 
visuo-spatial attention: Matrix Cancellation Features Target (MCFT). 
For the psychophysical study, we used a test battery developed to assess key cognitive 
components of the control of voluntary action. This test battery includes measures of: 1) 
sense of agency by the Temporal Binding task (TB)[16]; 2) inhibition by the Stop signal 
reaction time task (SSRT)[17]; 3) intentional stopping by the Marble Task (modified version 
of the task by Schel et al.[18]).4) decision making under risk: Balloon Analogue Risk Task 
(BART) (modified version of the task by Lejuez et al[19]).  
Specific details of each test are given in Supplementary material online. Figure 1 illustrates 
the study design.  
STATISTICAL ANALYSIS 
Demographical data were compared across the 3 groups (PD-ICB, PD-no-ICB, HC) using 
the Kruskall-Wallis test. Two-groups comparisons (HC vs PD and PD-ICB vs PD-no-ICB) 
were computed for all clinical, psychiatric and cognitive variables by means of Mann-
Whitney U test. Behavioural findings were compared across different groups (PD-ICB, PD-
no-ICB, HC) by means of one-way analysis of variance (ANOVA) with “group” as 
dependent variable.   
Correlational analysis was conducted using Spearman bivariate correlations. To control for 
potential underlying causes of differences in action binding in the patients groups we 
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conducted a multiple linear regression analysis where action binding was the dependent 
variable and group (dummy-coded ICB/no-ICB), disease duration, medication (LEDD), 
BDI, HARS and AES were the regressors. Statistical analysis was performed by software 
program SPSS-21 (SPSS Inc; Chicago, IL, USA). Data are shown as mean values ± 
standard deviations. Significance level was set at p < 0.05 unless differently specified.  
RESULTS  
The three groups did not differ for age, education level and gender distribution.  Mann-
Whitney U tests revealed that PD-ICB had significantly longer disease duration than PD-
no-ICB and had a higher total LEDD; however, D-Ag LEDD did not differ between the two 
groups. No other significant difference was found between the two PD groups (table 1).  
Compared to HC, PD patients reported more severe depression, anxiety and apathy. Only 
apathy was more pronounced in the PD-ICB group compared to PD-no-ICB. Global 
cognitive function as per MOCA was comparable between HC and PD and between PD-
ICB and PD-no-ICB. When evaluating specific cognitive domains, PD had lower scores 
compared to HC in tests evaluating working memory (digit span forward), 
attentive/executive functions (digit span backward, phonological fluency, semantic fluency, 
TMT-A), and attentional visual conjunction search (MFCT). However, no difference in any 
cognitive domain was detected between PD-no-ICB and PD-ICB (supplementary table 1). 
Results from psychophysical testing are shown in Table 2. For action binding, one-way 
ANOVA showed a significant main effect of group due to a significant difference between 
PD-ICB and HC (p=0.004) and PD-ICB and PD-no-ICB (p=0.04), by post-hoc t-test (Figure 
2). PD-no-ICB and HC were not different (p=1). No significant difference among groups 
was found for tone binding. Given that PD-ICB and PD-no-ICB differed by disease duration 
and total LEDD, we conducted a one-way analysis of covariance (ANCOVA) to compare 
the performance of the two PD groups on each psychophysical task taking into account 
these variables. Although groups were matched for LEDD dopamine-agonists, we added 
this variable as a covariate in the ANCOVA analysis in order to control for a potential 
impact of therapy variability on the behavioural findings. After adjusting for disease 
duration, LEDD dopamine-agonists and total LEDD, one-way ANCOVA showed that the 
group effect on action binding remained significant (F=5.2; p=0.028; partial eta squared 
value of 0.1), either when co-varying for disease duration only (F=5.3; p=0.03), for total 
LEDD only (F=6.2, p=0.02) or for LEDD dopamine-agonists only (F=4.0; p=0.05). We also 
compared the standard deviations across repeated trials of time estimates in each 
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condition, as a measure of perceptual timing abilities. Inconsistent time estimation, for 
example due to poor attention, would produce high standard deviation of timing estimates 
across trials.  However, we found no significant difference among groups for baseline 
action, baseline tone, operant action and operant tone conditions. This finding excludes 
the possible effect of differences among groups in temporal judgement abilities, which 
might have influenced the results.  
One-way ANOVA showed a significant main effect of group in 50% quantile SSRT.  This 
was due to impaired stopping ability in PD-no-ICB (p=0.01) but not in PD-ICB (p=0.3) 
compared to HC. PD groups did not differ in the quantile SSRT (p=0.1). However, after 
adjusting for disease duration and total LEDD, one-way ANCOVA showed that the group 
effect on the 50% quantile SSRT was no longer significant (F=2.7; p=0.1).  
One-way ANOVA showed no difference between groups in each of the measures of the 
Marble task and the BART (Table 2). One-way ANOVA showed a significant difference 
among groups in terms of number of green marbles missed in the Marble Task (p=0.01, F 
4.9; Table 2).  However, after controlling for differences in disease duration, total LEDD 
and LEDD dopamine-agonists (one-way ANCOVA) there was no significant difference 
among groups for this variable and for any of the other variables in the Marble task and the 
BART. Thus differences between groups on these tasks might reflect variation in 
medication use and disease duration, rather than a pure effect of ICB. 
Spearman’s bivariate correlations, were conducted in each group separately (PD and HC 
groups) to examine the relation between binding task measures and the other 
psychometric variables (i.e., BDI, HARS, AES). This revealed a significant correlation in 
the overall PD group between anxiety by HARS score and tone binding and between total 
LEDD and tone binding. Spearman rank correlation analysis in the PD-ICB group 
demonstrated a significant correlation between total LEDD and tone binding (r=0.5, 
p=0.01). No significant correlation was found between D-Ag LEDD, BDI, HARS, AES, 
disease duration (Supplementary table 2) or QUIP-RS (Supplementary table 3) and any 
measure of the psychophysical tasks after correcting for multiple comparisons.   
Multiple linear regression with action binding as dependent variable and BDI, HARS, AES, 
disease duration, LEDD and patient groups (dummy-coded ICB/nonICB) as regressors 
showed that ICB was a significant predictor of action binding performance (b=0.4, 
SE=27.8, p=0.03, 95% CI [4.7, 118.5])  after controlling for affective, cognitive and disease 
related factors (Supplementary table 4).  
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DISCUSSION 
Our results show that PD patients with ICB have abnormally strong binding in the 
perceived time of an action towards its subsequent outcome, compared to both PD 
patients without ICB and to healthy subjects.  In contrast, we could not find any differences 
in tasks evaluating externally and internally triggered inhibition, or in risk/reward-based 
decision-making. The strength of this study is that we have explored several domains 
relevant to action control in patients with Parkinson’s disease with and without ICB, using a 
broad range of psychomotor tasks. The tasks assessed reward-related behaviour, 
inhibition (externally and internally triggered) and sense of agency.  Specifically, we 
employed the intentional binding task as a marker of sense of agency for voluntary action.  
The pairing of an outcome (a tone) with a self-paced action alters the perceived timing of 
these events compared to judgements of timing of action or a tone occurring alone. The 
temporal attraction or “binding” between self-generated actions and their outcomes has 
been suggested to be a quantitative index of awareness of action or agency [9]. In healthy 
people the “binding” effect is asymmetric, in that it is strongest for the perceived timing of 
the tone which is perceived to move back in time towards the time of the action more than 
the perceived timing of the action moves towards the time of the tone. This asymmetry is 
often interpreted in terms of optimal integration between action and tone events [20], with 
each event attracting the other in proportion to its perceptual saliency.  
A novel finding of our study demonstrates that PD-ICB have an abnormally large shift in 
perceived timing of the action towards the tone, compared to PD without ICB and healthy 
subjects. The intentional binding paradigm was already tested by Moore and co-workers in 
nine PD patients On and Off medication, but ICB status was not investigated [10]. In that 
study, the typical asymmetry of the binding effect was evident in PD Off medication 
similarly to PD-no-ICB in our sample, whereas levodopa seemed to enhance action 
binding in PD [10]. In our analysis, PD-ICB maintained a stronger action binding than PD-
no-ICB, also after adjusting for total LEDD and disease duration; moreover, the two patient 
groups did not differ by UPDRS-III or Hoen-Yahr stage, although we have to acknowledge 
that activity of daily living (by UPDRS-II) and complications of therapy (by UPDRS IV) were 
more pronounced in PD-ICB, although not significantly. This supports the view that a 
larger shift in action-binding specifically may be related to ICB rather than to dopaminergic 
treatment or disease severity and duration. 
Our results suggest that agency may be weakened in patients with PD-ICB because of a 
disturbance in perceptual processing that causes actions to be more strongly attracted 
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towards outcomes. However, we cannot determine whether the altered perceptual 
salience predominantly affects actions or outcomes in ICB patients. An abnormally strong 
representation of the outcome should have made patients adjust their behaviour on the 
BART task, making them more sensitive to the effect of risk level and its effect on 
outcome. As we did not find any difference between groups in risk-taking on the BART, we 
propose that an abnormally weak representation of action in ICB is the explanation for the 
increased action binding.  
The lack of functional neuroimaging in our study does not allow us to define the neural 
networks underlying increased action binding in ICB patients but we hypothesize a central 
role for pre-supplementary motor area (SMA) based on previous experimental studies [21, 
22]. Indeed, increased action binding has been found also in the most affected hand of 
patients with cortical basal syndrome (CBS) and was correlated to the severity of alien 
limb and apraxia as well to structural and functional changes in pre-SMA and in its 
connections to prefrontal cortex [21]. The greater motor severity of CBS coupled with high-
level sensory deficits and apraxia [21] might explain why CBS with alien limb phenomena 
can produce complete loss of agency attribution (“it isn’t me moving my hand”). On the 
other side, PD-ICB attribute the action to themselves, but the subjective experience of 
volition associated with the action itself is weak (“I know I am acting but I don’t know what 
I’m doing”).   
Our result cannot readily be explained by deficits in reward-related decision-making, as 
our binding task was valence-free. Previous functional neuroimaging studies have reported 
changes in reward-associated areas in PD with ICD, interpreted as a result of increased 
sensitivity of reward-related areas to dopamine-agonists [23-24]. Our data do not 
contradict these studies, as we only evaluated one component of reward-related decision-
making, namely risk-taking behaviour.  However, we rather suggest that other 
mechanisms may also contribute to the pathophysiology of ICB, in addition to the well-
known effect on valence.  For example, the importance of dopamine transmission for 
salience processing has also been emphasised in recent accounts of psychosis [25]. 
Further, though salience and valence are highly correlated, they do involve partially 
dissociable networks.  These networks overlap in key areas such as the ventral striatum, 
which is known to be important in the pathophysiology of PD and the mechanism of action 
of dopaminergic medication. 
ICB patients did not differ from healthy volunteers nor from patients without ICB in the 
BART task of decision-making, and specifically of risk-taking. The inconsistency of 
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previous literature on risk-taking behaviour in PD-ICB may be due to methodological 
differences, driven by different tasks employed (BART, Iowa Gambling Task, other 
gambling tasks), different clinical characteristics of patients or different pharmacological 
conditions (“On” or “Off” medication) [6,7,26-28]. Yet, our data are in line with previous 
studies showing no difference in the BART between PD patients with and without ICB 
tested “On” medication [27] or both “On” and “Off” [6]. However, in the study by Claassen 
and co-workers [6], only PD-ICB patients tended to increase risk-taking during “On” 
compared to “Off” state [6].  
We also evaluated measures of reactive and voluntary inhibition demonstrating that 
patients with and without ICB performed similarly in both externally-triggered inhibition 
(SSRT) and internally triggered inhibition tasks (Marble Task).  Patients with PD have 
previously been reported to be impaired in the SSRT, a task used as a measure of 
reactive inhibition which is not modified by dopaminergic medication [29]. In our study, a 
longer SSRT was demonstrated in the PD-no-ICB group compared to HC, although post-
hoc analysis did not show differences between PD-ICB and PD-no-ICB. The SSRT results 
are in line with previous studies showing no differences between patients with and without 
ICB in other tasks assessing reactive inhibitory control, including the Stroop test [30] and a 
go/no-go task [5]. Our results also suggest that the “whether” component of action control 
tested by the Marble Task is unaffected by PD itself or the presence of ICB. 
We acknowledge limitations to our study, including the lack of evaluation of the role of 
dopaminergic drugs (patients were tested only ‘On’ medication).  However, this is the most 
real day-to-day life condition, since patients are usually on treatment in everyday life; 
moreover, the binding effect remained significant when correcting for LEDD. Additionally, 
given the lack of functional neuroimaging, we can only speculate on the neural basis of the 
behavioural effects observed in this study.  
In conclusion, our data provide some support for the hypothesis that agency in ICB is 
impaired as a result of an abnormally weak representation of action, such that actions are 
more readily captured by outcomes. If the normal regulatory signals for action are weak or 
absent, then specific salient outcomes could “capture” behaviour, resulting in actions 
occurring without a strong experience of endogenous voluntary control. This finding 
contributes to the pathophysiology of ICB in PD, in addition to previously reported deficits 
in reward-related action control.  Our finding of altered experience of volition opens new 
perspectives on future therapeutic management of ICB. 
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FIGURES LEGEND 
Figure 1. Study design. The psychophysiological battery included tests evaluating the 
sense of agency (temporal binding task, panel A-C), motor stopping (Stop signal reaction 
time, panel D), intentional inhibition (modified version of the Marble task, panel E) and 
decision-making under risk (Balloon Analogue Risk Task, panel F). See text for details and 
references for each single task. 
Figure 2. Action binding in PD according to ICB status. Parkinson’s disease (PD) 
patients with impulsive compulsive behaviours (ICB) showed a significantly stronger action 
binding than healthy controls (p=0.004), and patients without ICB (p=0.04).  There was no 
difference between patients without ICB and healthy controls. Tone binding and overall 
binding did not differ among the three groups. 
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Table 1:  Demographic and clinical data in healthy controls (HC) and in Parkinson’s 
disease patients (PD) with and without impulsive compulsive behaviours (ICB) 
  HC PD-no-ICB PD-ICB p-values 
Sample (n) 19 19 19  - 
Age (years) 52.6 (7.4) 56.9 (8.4) 53.6 (9.3) p =0.3 
Gender (male) 8 11 12 p=0.4 
Education level (yrs) 15.1 (1.9) 13.2 (4.60) 12.8 (3.7) p =0.1 
Disease duration (years) - 5.4 (2.5) 7.8 (4.1) p =0.008* 
LEDD total (mg) - 544.9 (344.5) 790.0 (264.6) p =0.02* 
LEDD D-ag (mg) - 127.5 (143.8) 196.6 (167.9) p =0.2 
HY - 1.5 (0.4) 1.6 (0.5) 
 
p = 0.6 
UPDRS 
UPDRS-I - 1.6 (1.5) 2.4 (2.1) p =0.2 
UPDRS-II - 5.4 (3.8) 7.6 (3.8) p =0.07 
UPDRS-III - 12.2 (7.4) 15.4 (7.3) p =0.2 
UPDRS-IV - 2.5 (3.2) 4.5 (3.5) p =0.07 
ICB 
Pathological 
Gambling 0 0 4   
Hypersexuality 0 0 12   
Compulsive 
shopping 0 0 11   
Binge eating 0 0 8   
Hobbyism/punding 0 0 11   
DDS 0 0 3   
 
HY = Hoehn-Yahr stage; LEDD = levodopa equivalent daily dose; UPDRS = Unified Parkinson’s 
disease rating scale (UPDRS); DDS = dopamine dysregulation syndrome.  
Values are means ± Standard deviation. Comparisons were made by Mann-Whitney U test or chi-
square test (for categorical data). Values in bold indicate significant differences (p < 0.05). 
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Table 2: Binding task, SSRT, Marble Task and BART in healthy controls (HC) and 
Parkinson’s disease (PD) according to the presence of impulsive-compulsive 
behaviour (ICB) 
 
 
BART =Balloon Analog Risk Task for reward sensitivity; SSRT = Stop Signal Reaction Time; 
RT = reaction time; TJE = Temporal Judgment Error. F and p-values refer to one-way 
factorial ANOVA with group as dependent variable (p < 0.05). * Two HC were excluded from 
the analysis due to negative SSRT values. Values are means ± Standard deviation.  
 
 
HC PD-no-ICB PD-ICB F (2,54) p-value  
 TJE (ms) Action (Baseline) -28 ± 50 -45 ± 51 -18 ± 47 F = 1.5,  
p = 0.2 
Tone (Baseline) -34 ± 46 -53 ± 55 -52 ± 85 F = 0.5 
p = 0.6 
Action (Operant) -27 ± 46 * -28 ± 56 * 47 ± 80 * F = 9.1  
p < 0.001 
Tone (Operant) -152 ± 90 -173 ± 77 -137 ± 92 F = 0.8 
p = 0.4 
Binding (mean shift of TJE 
from baseline, ms) 
Action (ms) 1 ± 39 * 17 ± 62 * 65 ± 68 * F = 6.3 
p = 0.004  
Tone (ms) -118 ± 86 -120 ± 82 -85 ± 96 F = 0.9 
p = 0.4 
SSRT Quantile SSRT (ms) 230.1 ± 
77.1 
312.9 ± 
102.5 
261.5 ± 
94.1 
F (2,51)* =3.6 
P
 
= 0.03 
Stopped 0.6 ± 0.1 0.5 ± 0.1 0.6 ± 0.05 P(2,51)=0.1, 
F=1.9 
Reversal 16.8 ± 4.9 17.2 ± 4.3 17.9 ± 2.9 P(2,51)=0.7, 
F=0.4 
Post error slowing 50.9 ± 78.9 47.2 ± 68.7 71.7 ± 77.5 P(2,51)=0.6, 
F=0.6 
Marble Task RT white (ms) 320.8 ± 98.2 
367.9 ± 
143.2 
337.1 ± 
69.8 P=0.4, F=0.9 
RT green (ms) 285.5 ± 51.9 322.8 ± 74.5 
312.9 ± 
59.8 P=0.2, F=1.8 
White stopped 0.5 ± 0.1 0.5 ± 0.2 0.6 ± 0.1 P=0.6, F=0.5 
Green missed 0.3 ± 0.1 0.4 ± 0.2 0.5 ± 0.1 P=0.01, F =4.9 
BART Inflation low risk 3.4 ± 1.3 2.9 ± 1.1 3.2 ± 0.9 P=0.3, F=1 
Inflation high risk 2.1 ± 0.6 2.1 ± 0.5 2.2 ± 0.5 P=0.8, F=0.2 
Risk adjustment 1.4 ± 0.9 0.8 ± 0.8 0.9 ± 0.9 P=0.1, F=1.9 
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• We assessed the relationship between impulsive-compulsive behavior (ICB) and 
action control in PD. 
• PD-ICB have abnormally strong action binding. 
• This effect remained significant when correcting for disease duration and LEDD 
• The abnormality of action binding suggests that impaired sense of agency is 
related to ICB in PD. 
 
 
 
